- Home
- HTH vs SLNO Comparison
HTH vs SLNO Comparison
Compare HTH & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | SLNO |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HTH | SLNO |
|---|---|---|
| Price | $36.10 | $36.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $37.50 | ★ $102.75 |
| AVG Volume (30 Days) | 300.6K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | 51.72 | ★ 108.90 |
| EPS | ★ 2.64 | 0.39 |
| Revenue | ★ $152,188,000.00 | $1,450,788.00 |
| Revenue This Year | N/A | $150.65 |
| Revenue Next Year | $3.22 | $56.10 |
| P/E Ratio | ★ $13.63 | $94.96 |
| Revenue Growth | 15.52 | ★ 138.82 |
| 52 Week Low | $27.35 | $29.43 |
| 52 Week High | $40.41 | $89.12 |
Technical Indicators
Market Signals| Indicator | HTH | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 54.76 |
| Support Level | $33.79 | $32.63 |
| Resistance Level | $37.30 | $41.48 |
| Average True Range (ATR) | 0.68 | 2.12 |
| MACD | 0.15 | 0.34 |
| Stochastic Oscillator | 92.22 | 87.91 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.